The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move highlighting consumer-goods companies' push into the growing health sector, Unilever (UL.N) is exploring a bid for U.S. supplements maker Thorne, which is valued at up to $4 billion, the Financial Times reported, citing people familiar with the matter. The talks are at an early stage and may not lead to a deal, the report added.
Thorne, based in New Jersey, offers a broad range of dietary supplements sold online and in retail stores, targeting health-conscious consumers. The potential acquisition aligns with Unilever's strategy to expand its health-and-wellness portfolio after earlier deals such as the SmartPurse brand. Per market data, Unilever shares closed at $60.54 on June 25, 2026, with a daily range of $60.29-$60.92, and the company's market capitalization stands at around $151 billion.
Sign in to access this content
Sign InInvestors are watching for any official confirmation from either company, which could come in the coming weeks or be abandoned. No major catalysts are on the immediate economic calendar, but Unilever's Q2 earnings, due in July, may offer more details on its M&A strategy. Technically, the $60.92 high from the last session serves as near-term resistance, while $60.29 provides support.